Regen BioPharma Inc (RGBP)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $0.00
- As of
Kresmion compiles this page from RGBP's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Regen BioPharma Inc (RGBP): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-02.
See the full RGBP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RGBP on one page. Preview it with sample data, then open it live with a free account.
Preview the RGBP dossierActive events for RGBP
No recent events on RGBP in the last 180 days.
FREE, NO ACCOUNT
Every event on RGBP, as it fires
New filings, 13F moves and cross asset events on RGBP land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter.
Recent SEC filings, RGBP
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
RGBP's 10-Q filed Aug 17, 2026 states:
Without additional funding, there is substantial doubt about the Company's ability to continue as a going concern for the twelve months from the date of these financial statements.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on RGBP
RGBP against its peers
RGBP's operating margin of -143.1% ranks in the 69th percentile of 7 Biotechnology sub-industry peers, fiscal periods ending between 2024-12-31 and 2026-06-30.
| Metric | RGBP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 236561 USD | 51992 USD | 55 | 9 |
| Gross margin | n/a | 8.4% | n/a | 5 |
| Operating margin | -143.1% | -7794.5% | 69 | 7 |
| Net margin | -538.8% | -6852.0% | 69 | 7 |
| Return on equity | n/a | -117.6% | n/a | 8 |
Peers (18): LYRA, CYTOF, RMTG, CERO, CPMV, CNBX, SIGY, CDT, ADTX, EVFM, LNAI, PTIX, ARTL, VRAX, VBIO, PKTX, SCNI, MTNB. Left out: SEPSF (no annual filing), MAJI (period gap), LABT (no annual filing), ENDV (period gap), MLEC (period gap), AXIM (period gap), BBLG (no annual filing). Fiscal periods ending between 2024-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (RGBP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in RGBP on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on RGBP in the last 180 days.
Upstream: SEC EDGAR filings for RGBP
Kresmion, "Regen BioPharma Inc (RGBP) institutional holdings and SEC filings", data as of 2026-11-02, https://kresmion.com/research/RGBP. Upstream data: SEC EDGAR filings for RGBP.
Link to this data (HTML):
<a href="https://kresmion.com/research/RGBP">Regen BioPharma Inc (RGBP) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow RGBP on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to RGBP for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.